Literature DB >> 24388426

Dopaminergic basis of salience dysregulation in psychosis.

Toby T Winton-Brown1, Paolo Fusar-Poli2, Mark A Ungless3, Oliver D Howes4.   

Abstract

Disrupted salience processing is proposed as central in linking dysregulated dopamine function with psychotic symptoms. Several strands of evidence are now converging in support of this model. Animal studies show that midbrain dopamine neurons are activated by unexpected salient events. In psychotic patients, neurochemical studies have confirmed subcortical striatal dysregulation of dopaminergic neurotransmission, whereas functional magnetic resonance imaging (fMRI) studies of salience tasks have located alterations in prefrontal and striatal dopaminergic projection fields. At the clinical level, this may account for the altered sense of meaning and significance that predates the onset of psychosis. This review draws these different strands of evidence together in support of an emerging understanding of how dopamine dysregulation may lead to aberrant salience and psychotic symptoms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  dopamine; psychosis; reward; salience; schizophrenia

Mesh:

Year:  2014        PMID: 24388426     DOI: 10.1016/j.tins.2013.11.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  88 in total

1.  Dopamine neuron dependent behaviors mediated by glutamate cotransmission.

Authors:  Susana Mingote; Nao Chuhma; Abigail Kalmbach; Gretchen M Thomsen; Yvonne Wang; Andra Mihali; Caroline Sferrazza; Ilana Zucker-Scharff; Anna-Claire Siena; Martha G Welch; José Lizardi-Ortiz; David Sulzer; Holly Moore; Inna Gaisler-Salomon; Stephen Rayport
Journal:  Elife       Date:  2017-07-13       Impact factor: 8.140

Review 2.  Spine dynamics in the brain, mental disorders and artificial neural networks.

Authors:  Haruo Kasai; Noam E Ziv; Hitoshi Okazaki; Sho Yagishita; Taro Toyoizumi
Journal:  Nat Rev Neurosci       Date:  2021-05-28       Impact factor: 34.870

3.  Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging.

Authors:  Simon Kaller; Michael Rullmann; Marianne Patt; Georg-Alexander Becker; Julia Luthardt; Johanna Girbardt; Philipp M Meyer; Peter Werner; Henryk Barthel; Anke Bresch; Thomas H Fritz; Swen Hesse; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

4.  What you want may not be what you like: A test of the aberrant salience hypothesis in schizophrenia risk.

Authors:  Lilian Yanqing Li; Mayan K Castro; Elizabeth A Martin
Journal:  Cogn Affect Behav Neurosci       Date:  2020-08       Impact factor: 3.282

5.  Levodopa administration modulates striatal processing of punishment-associated items in healthy participants.

Authors:  Bianca C Wittmann; Mark D'Esposito
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 6.  Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features.

Authors:  Jennifer K Forsyth; David A Lewis
Journal:  Trends Cogn Sci       Date:  2017-07-25       Impact factor: 20.229

Review 7.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

8.  Impaired effort allocation in patients with schizophrenia.

Authors:  Michael T Treadway; Joel S Peterman; David H Zald; Sohee Park
Journal:  Schizophr Res       Date:  2014-12-05       Impact factor: 4.939

9.  Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.

Authors:  Luke E Sebel; Steven M Graves; C Savio Chan; D James Surmeier
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

Review 10.  An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Biol Psychiatry       Date:  2016-06-01       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.